]> 2026-07-31T09:39:49+00:00 WBR0163 0 en Breast cancer Breast cancer is not currently treated with tyrosine kinase inhibitors. HER2-positive breast cancers may be treated with trastuzamab. Gastrointestinal stromal tumor The pathogenesis of GIST tumors involves a gain-of-function mutation in the ''KIT'' proto-oncogene, which encodes a transmembrane receptor for stem cell factor that includes a tyrosine kinase component in its intracytoplasmic region. Similar to CML, imatinib has demonstrated efficacy in GIST, whereby it similarly inhibits the tyrosine kinase receptor KIT in a similar fashion to its inhibition of the tyrosine kinase receptor BCR-ABL fusion protein. Hepatocellular carcinoma HCC may be secondary to chronic viral hepatitis and/or cirrhosis. Hepatocellular carcinoma (HCC) is not treated with imatinib. Mantle cell lymphoma Mantle cell lymphoma is a rare non-Hodgkin’s lymphoma that affects elderly males. Imatinib is not used to treat Mantle cell lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma MALT Lymphoma is associated with ''H. pylori'' infection and is not susceptible to imatinib therapy. For early and localized MALT lymphoma, treatment of underlying ''H. pylori'' infection by antibiotics is often sufficient to induce tumor regression. Pharmacology A 45-year-old man presents to his primary care physician for fatigue and weight loss of 10 pounds over the past month. On physical examination, the spleen is palpable 7 cm below the costal margin, and several bruises are observed across the body. Laboratory testing is significant for an elevated white blood cell count and reduced platelet count. Bone marrow biopsy demonstrates hyperplastic granulocytes which are positive for a t(9;22) translocation. The patient is started on an inhibitor of the fusion gene produced by this translocation. The administered drug is most likely also effective to treat which of the following conditions? B Hematology Oncology 2020-10-27T23:33:17Z 2459150.4814468 WBR0163